menu toggle
Thursday, November 26 - Friday, November 27
Cencora will be closed on Thursday, November 26 in observance of the Thanksgiving holiday. There will be no deliveries on this day and our Customer Service and Customer Systems Support teams will be unavailable. Our offices will also be closed on Friday, November 27. While deliveries for non-refrigerated product will be attempted on Friday, our offices will be closed. Customer Service may be limited and Customer System Support will also be limited and available by email only. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.

August 4, 2022

Now available ULTOMIRIS®

ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous or subcutaneous use, is a complement inhibitor indicated for:
• the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)

• the treatment of adult and pediatric patients one month of age and olderwith atypical hemolytic uremic syndrome (aHUS) to inhibitcomplement-mediated thrombotic microangiopathy (TMA)

Limitations of Use:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS)

• the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive

View full prescribing information.